Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency

BACKGROUND AND OBJECTIVES: There are conflicting views as to whether testing for biotinidase deficiency (BD) ought to be incorporated into universal newborn screening (NBS) programs. The aim of this study was to evaluate the cost-effectiveness of adding BD to the panel of conditions currently screened under the national NBS program in Spain. METHODS: We used information from the regional NBS program for BD that has been in place in the Spanish region of Galicia since 1987. These data, along with other sources, were used to develop a cost-effectiveness decision model that compared lifetime costs and health outcomes of a national birth cohort of newborns with and without an early detection program. The analysis took the perspective of the Spanish National Health Service. Effectiveness was measured in terms of quality-adjusted life years (QALYs). We undertook extensive sensitivity analyses around the main model assumptions, including a probabilistic sensitivity analysis. RESULTS: In the base case analysis, NBS for BD led to higher QALYs and higher health care costs, with an estimated incremental cost per QALY gained of $24 677. Lower costs per QALY gained were found when conservative assumptions were relaxed, yielding cost savings in some scenarios. The probability that BD screening was cost-effective was estimated to be >70% in the base case at a standard threshold value. CONCLUSIONS: This study indicates that NBS for BD is likely to be a cost-effective use of resources.

[1]  E. C. Neto,et al.  Newborn screening for biotinidase deficiency in Brazil: biochemical and molecular characterizations. , 2004, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[2]  S. Waisbren,et al.  Cognitive function in early treated biotinidase deficiency: Follow-up of children detected by newborn screening , 1995 .

[3]  C. L. Kien,et al.  Complete Biotinidase Deficiency Presenting as Reversible Progressive Ataxia and Sensorineural Deafness , 2002, Journal of child neurology.

[4]  Wendy J. Ungar,et al.  Challenges in Health State Valuation in Paediatric Economic Evaluation , 2011, PharmacoEconomics.

[5]  F. Martinón-Torres,et al.  [Biotinidase deficiency: importance of its neonatal diagnosis and early treatment]. , 1999, Anales espanoles de pediatria.

[6]  J. L. Pinto,et al.  [What is an efficient health technology in Spain?]. , 2002, Gaceta sanitaria.

[7]  American Academy of Pediatrics Committee on Genetics: Newborn screening fact sheets. , 1989, Pediatrics.

[8]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[9]  B. Wolf,et al.  Hearing loss is a common feature of symptomatic children with profound biotinidase deficiency. , 2002, The Journal of pediatrics.

[10]  R. Regan,et al.  Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom , 2007, Genomic Medicine.

[11]  B. Wolf,et al.  Biotinidase deficiency: Initial clinical features and rapid diagnosis , 1985, Annals of neurology.

[12]  C. Pérez-Cerdá,et al.  Results of neonatal and selective screening for biotinidase deficiency , 1987, Journal of Inherited Metabolic Disease.

[13]  D. Feeny,et al.  QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique , 2010, Expert review of pharmacoeconomics & outcomes research.

[14]  B. Wolf,et al.  Neonatal screening for biotinidase deficiency in Hungary: Clinical, biochemical and molecular studies , 2003, Journal of Inherited Metabolic Disease.

[15]  J. Leonard,et al.  Biotinidase Deficiency: a Treatable Leukoencephalopathy , 2004, Neuropediatrics.

[16]  B. Wolf.  Biotinidase deficiency: “if you have to have an inherited metabolic disease, this is the one to have” , 2012, Genetics in Medicine.

[17]  Xuefan Gu,et al.  Diagnosis, treatment, follow-up and gene mutation analysis in four Chinese children with biotinidase deficiency , 2009, Journal of Inherited Metabolic Disease.

[18]  S. Korman,et al.  Reversible deafness caused by biotinidase deficiency. , 2000, Pediatric neurology.

[19]  M. Cornel,et al.  Evaluation of population newborn screening practices for rare disorders in member states of the European Union , 2010, Orphanet Journal of Rare Diseases.

[20]  P. Ozand,et al.  Biotinidase deficiency: a treatable genetic disorder in the Saudi population. , 1999, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[21]  B. Wolf.  Clinical issues and frequent questions about biotinidase deficiency. , 2010, Molecular genetics and metabolism.

[22]  J. A. Sacristán,et al.  Qué es una tecnología sanitaria eficiente en España , 2002 .

[23]  R. Hussain,et al.  The influence of intellectual disability on life expectancy. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[24]  Z. Havass.  Neonatal screening for biotinidase deficiency in East-Hungary , 1991, Journal of Inherited Metabolic Disease.

[25]  A. Carroll,et al.  Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. , 2009, The Journal of pediatrics.

[26]  C. Kaye.  Newborn Screening Fact Sheets , 2006, Pediatrics.

[27]  Y. L. Loukas,et al.  High incidence of partial biotinidase deficiency cases in newborns of Greek origin. , 2013, Gene.

[28]  J. Mar,et al.  [A proposed guideline for economic evaluation of health technologies]. , 2010, Gaceta sanitaria.

[29]  Jaume Puig-Junoy,et al.  Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias , 2010 .

[30]  B. Wolf.  Worldwide survey of neonatal screening for biotinidase deficiency , 1991, Journal of Inherited Metabolic Disease.

[31]  K. Widhalm,et al.  Screening for biotinidase deficiency in Austria , 1995 .

[32]  S. Petrou,et al.  Estimating Preference-Based Health Utilities Index Mark 3 Utility Scores for Childhood Conditions in England and Scotland , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[33]  B. Wolf,et al.  Ophthalmologic findings in biotinidase deficiency. , 1993, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[34]  T. Suormala,et al.  Clinical and neuropsychological outcome in 33 patients with biotinidase deficiency ascertained by nationwide newborn screening and family studies in Austria , 2001, European Journal of Pediatrics.

[35]  P. Farrell,et al.  The magnitude and challenge of false-positive newborn screening test results. , 2000, Archives of pediatrics & adolescent medicine.

[36]  C. Scriver.  Community Genetics and Dignity in Diversity in the Quebec Network of Genetic Medicine , 2006, Public Health Genomics.

[37]  J. Campistol,et al.  Hallazgos clínicos y genéticos en pacientes con deficiencia de biotinidasa detectados en el cribado neonatal o selectivo de sordera o de enfermedades metabólicas hereditarias , 2011 .

[38]  Committee on Genetics , 2016, Pediatric Clinical Practice Guidelines & Policies.

[39]  Á. Schuler,et al.  High frequencies of biotinidase (BTD) gene mutations in the Hungarian population , 2010, Journal of Inherited Metabolic Disease.

[40]  D. B. Welling.  Long-Term Follow-Up of Hearing Loss in Biotinidase Deficiency , 2007, Journal of Child Neurology.

[41]  R. Schoos,et al.  [Programs of systematic screening in neonatology. Pharmaco-economic aspects]. , 1998, Revue medicale de Liege.

[42]  S. Downs,et al.  Parents' utilities for outcomes of occult bacteremia. , 2000, Archives of pediatrics & adolescent medicine.

[43]  C. Laberge,et al.  Prospective ascertainment of complete and partial serum biotinidase deficiency in the newborn , 1989, Journal of Inherited Metabolic Disease.

[44]  Aaron E. Carroll,et al.  Comprehensive Cost-Utility Analysis of Newborn Screening Strategies , 2006, Pediatrics.

[45]  T. Coşkun,et al.  Audiologic findings in children with biotinidase deficiency in Turkey. , 2007, International journal of pediatric otorhinolaryngology.

[46]  B. Wolf.  The neurology of biotinidase deficiency. , 2011, Molecular Genetics and Metabolism.

[47]  E. R. Baumgartner,et al.  Outcome in patients with profound biotinidase deficiency: relevance of newborn screening , 2004, Developmental medicine and child neurology.

[48]  B. Wolf,et al.  Characterization of seizures associated with biotinidase deficiency , 1993, Neurology.